HCPCS Level II code Q5122 designates the biosimilar pegfilgrastim-apgf (Nyvepria) in a 0.5 mg injection formulation. Pegfilgrastim biosimilars are clinically important for reducing febrile neutropenia risk in patients undergoing myelosuppressive chemotherapy, and coding clarity affects access and billing consistency across outpatient and hospital settings. Nationally, clear use of biosimilar HCPCS codes supports accurate reimbursement, utilization tracking, and biosimilar adoption.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of payer coverage patterns and coding considerations for Q5122, where available, and highlights clinical context for pegfilgrastim biosimilars.

Readers will learn: the clinical purpose of the code, typical sites of service for administration, and which major national payers are relevant for coverage considerations. The report summarizes available benchmarks and policy updates that affect billing and utilization of pegfilgrastim biosimilars. Data not available in the input will be noted where applicable.